First step: testing new drug in people with liver problems
NCT ID NCT06719128
Summary
This early study aimed to understand how a new drug, olomorasib, is processed by people with different levels of liver impairment compared to healthy people. It involved 46 participants who received a single dose, with a focus on measuring drug levels in the blood and checking for safety. The goal was to gather essential information to guide future studies and potential dosing for patients with liver conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation at Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33014, United States
-
Orange County Research Center
Lake Forest, California, 92630, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
Conditions
Explore the condition pages connected to this study.